Neurohormonal activation and the management of heart failure

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Heart failure is a complex and usually progressive disease process in which structural and functional disturbances in the left ventricle are accompanied by activation of the sympathetic nervous system (SNS) and the renin-angiotensin-aldosterone system (RAAS) (Thomas and Marks, Am J Cardiol, 41:233-43, 1978; Levine et al., Am J Cardiol, 49:1659-66, 1982; Cohn et al., N Engl J Med, 311:819-23, 1984). Before the 1970s, managing heart failure aimed at improving the functional deficit of the left ventricular pump and relieving the resultant fluid accumulation with diuretic therapy (Weber, J Am Coll Cardiol, 44(6):1308-10, 2004). Although diuretic therapy has remained a mainstay of treatment, inotropic drug therapy was associated with adverse effects and no improvement in survival (Lee et al., N Engl J Med, 306(12):699-705, 1982; Guyatt et al., Am J Cardiol, 61(4):371-5, 1988). Consequently, since the 1970s, pharmacologic management has shifted more toward reducing the vascular bed's opposition to left ventricular emptying and inhibiting the vasoconstrictor and growth-promoting influences of neurohormonal stimulation that leads to left ventricular structural changes or remodeling (Cohn, Circulation, 48(1):5-8, 1973; Guiha et al., N Engl J Med, 291(12):587-92, 1974; Mikulic et al., Circulation, 56(4 Pt 1):528-33, 1977; Cohn and Franciosa, Am J Med, 65(1):181-8, 1978). This shift in emphasis has resulted in reduced dependence on digitalis and other positive inotropic interventions and greater reliance on angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), beta-adrenergic receptor blockers, aldosterone inhibitors, and newer agents that appear to inhibit vasoconstrictor and growth-promoting forces that contribute to the progression of the disorder (CONSENSUS Trial Study Group, N Engl J Med, 316(23):1429-35, 1987; The SOLVD Investigators, N Engl J Med, 325(5):293-302, 1991; Cohn et al., N Engl J Med, 345(23):1667-75, 2001; Packer et al., N Engl J Med, 334(21):1349-55, 1996; McMurray et al., N Engl J Med, 371(11):993-1004, 2014). This chapter addresses the evidence for neurohormonal activation in heart failure, data demonstrating a favorable effect of these neurohormonal modulators on the course of heart failure, and future therapeutic strategies that may be effective in slowing the growing burden of heart failure in the developed world.

Original languageEnglish (US)
Title of host publicationCongestive Heart Failure and Cardiac Transplantation
Subtitle of host publicationClinical, Pathology, Imaging and Molecular Profiles
PublisherSpringer International Publishing
Pages239-246
Number of pages8
ISBN (Electronic)9783319445779
ISBN (Print)9783319445755
DOIs
StatePublished - Jun 1 2017

Fingerprint

Heart Failure
Vasoconstrictor Agents
Diuretics
Adrenergic beta-Antagonists
Digitalis
Angiotensin Receptor Antagonists
Receptors, Adrenergic, beta
Sympathetic Nervous System
Therapeutics
Renin-Angiotensin System
Growth
Aldosterone
Angiotensin-Converting Enzyme Inhibitors
Heart Ventricles
Blood Vessels
Research Personnel
Drug Therapy

Keywords

  • Heart failure
  • Neurohormonal activation
  • Renin-angiotensin system (RAS)
  • Renin-angiotensin-aldosterone system (RAAS)

Cite this

Cohn, J. N. (2017). Neurohormonal activation and the management of heart failure. In Congestive Heart Failure and Cardiac Transplantation: Clinical, Pathology, Imaging and Molecular Profiles (pp. 239-246). Springer International Publishing. https://doi.org/10.1007/978-3-319-44577-9_16

Neurohormonal activation and the management of heart failure. / Cohn, Jay N.

Congestive Heart Failure and Cardiac Transplantation: Clinical, Pathology, Imaging and Molecular Profiles. Springer International Publishing, 2017. p. 239-246.

Research output: Chapter in Book/Report/Conference proceedingChapter

Cohn, JN 2017, Neurohormonal activation and the management of heart failure. in Congestive Heart Failure and Cardiac Transplantation: Clinical, Pathology, Imaging and Molecular Profiles. Springer International Publishing, pp. 239-246. https://doi.org/10.1007/978-3-319-44577-9_16
Cohn JN. Neurohormonal activation and the management of heart failure. In Congestive Heart Failure and Cardiac Transplantation: Clinical, Pathology, Imaging and Molecular Profiles. Springer International Publishing. 2017. p. 239-246 https://doi.org/10.1007/978-3-319-44577-9_16
Cohn, Jay N. / Neurohormonal activation and the management of heart failure. Congestive Heart Failure and Cardiac Transplantation: Clinical, Pathology, Imaging and Molecular Profiles. Springer International Publishing, 2017. pp. 239-246
@inbook{4b397ee057ed466d89135a5b9c8bea29,
title = "Neurohormonal activation and the management of heart failure",
abstract = "Heart failure is a complex and usually progressive disease process in which structural and functional disturbances in the left ventricle are accompanied by activation of the sympathetic nervous system (SNS) and the renin-angiotensin-aldosterone system (RAAS) (Thomas and Marks, Am J Cardiol, 41:233-43, 1978; Levine et al., Am J Cardiol, 49:1659-66, 1982; Cohn et al., N Engl J Med, 311:819-23, 1984). Before the 1970s, managing heart failure aimed at improving the functional deficit of the left ventricular pump and relieving the resultant fluid accumulation with diuretic therapy (Weber, J Am Coll Cardiol, 44(6):1308-10, 2004). Although diuretic therapy has remained a mainstay of treatment, inotropic drug therapy was associated with adverse effects and no improvement in survival (Lee et al., N Engl J Med, 306(12):699-705, 1982; Guyatt et al., Am J Cardiol, 61(4):371-5, 1988). Consequently, since the 1970s, pharmacologic management has shifted more toward reducing the vascular bed's opposition to left ventricular emptying and inhibiting the vasoconstrictor and growth-promoting influences of neurohormonal stimulation that leads to left ventricular structural changes or remodeling (Cohn, Circulation, 48(1):5-8, 1973; Guiha et al., N Engl J Med, 291(12):587-92, 1974; Mikulic et al., Circulation, 56(4 Pt 1):528-33, 1977; Cohn and Franciosa, Am J Med, 65(1):181-8, 1978). This shift in emphasis has resulted in reduced dependence on digitalis and other positive inotropic interventions and greater reliance on angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), beta-adrenergic receptor blockers, aldosterone inhibitors, and newer agents that appear to inhibit vasoconstrictor and growth-promoting forces that contribute to the progression of the disorder (CONSENSUS Trial Study Group, N Engl J Med, 316(23):1429-35, 1987; The SOLVD Investigators, N Engl J Med, 325(5):293-302, 1991; Cohn et al., N Engl J Med, 345(23):1667-75, 2001; Packer et al., N Engl J Med, 334(21):1349-55, 1996; McMurray et al., N Engl J Med, 371(11):993-1004, 2014). This chapter addresses the evidence for neurohormonal activation in heart failure, data demonstrating a favorable effect of these neurohormonal modulators on the course of heart failure, and future therapeutic strategies that may be effective in slowing the growing burden of heart failure in the developed world.",
keywords = "Heart failure, Neurohormonal activation, Renin-angiotensin system (RAS), Renin-angiotensin-aldosterone system (RAAS)",
author = "Cohn, {Jay N.}",
year = "2017",
month = "6",
day = "1",
doi = "10.1007/978-3-319-44577-9_16",
language = "English (US)",
isbn = "9783319445755",
pages = "239--246",
booktitle = "Congestive Heart Failure and Cardiac Transplantation",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Neurohormonal activation and the management of heart failure

AU - Cohn, Jay N.

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Heart failure is a complex and usually progressive disease process in which structural and functional disturbances in the left ventricle are accompanied by activation of the sympathetic nervous system (SNS) and the renin-angiotensin-aldosterone system (RAAS) (Thomas and Marks, Am J Cardiol, 41:233-43, 1978; Levine et al., Am J Cardiol, 49:1659-66, 1982; Cohn et al., N Engl J Med, 311:819-23, 1984). Before the 1970s, managing heart failure aimed at improving the functional deficit of the left ventricular pump and relieving the resultant fluid accumulation with diuretic therapy (Weber, J Am Coll Cardiol, 44(6):1308-10, 2004). Although diuretic therapy has remained a mainstay of treatment, inotropic drug therapy was associated with adverse effects and no improvement in survival (Lee et al., N Engl J Med, 306(12):699-705, 1982; Guyatt et al., Am J Cardiol, 61(4):371-5, 1988). Consequently, since the 1970s, pharmacologic management has shifted more toward reducing the vascular bed's opposition to left ventricular emptying and inhibiting the vasoconstrictor and growth-promoting influences of neurohormonal stimulation that leads to left ventricular structural changes or remodeling (Cohn, Circulation, 48(1):5-8, 1973; Guiha et al., N Engl J Med, 291(12):587-92, 1974; Mikulic et al., Circulation, 56(4 Pt 1):528-33, 1977; Cohn and Franciosa, Am J Med, 65(1):181-8, 1978). This shift in emphasis has resulted in reduced dependence on digitalis and other positive inotropic interventions and greater reliance on angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), beta-adrenergic receptor blockers, aldosterone inhibitors, and newer agents that appear to inhibit vasoconstrictor and growth-promoting forces that contribute to the progression of the disorder (CONSENSUS Trial Study Group, N Engl J Med, 316(23):1429-35, 1987; The SOLVD Investigators, N Engl J Med, 325(5):293-302, 1991; Cohn et al., N Engl J Med, 345(23):1667-75, 2001; Packer et al., N Engl J Med, 334(21):1349-55, 1996; McMurray et al., N Engl J Med, 371(11):993-1004, 2014). This chapter addresses the evidence for neurohormonal activation in heart failure, data demonstrating a favorable effect of these neurohormonal modulators on the course of heart failure, and future therapeutic strategies that may be effective in slowing the growing burden of heart failure in the developed world.

AB - Heart failure is a complex and usually progressive disease process in which structural and functional disturbances in the left ventricle are accompanied by activation of the sympathetic nervous system (SNS) and the renin-angiotensin-aldosterone system (RAAS) (Thomas and Marks, Am J Cardiol, 41:233-43, 1978; Levine et al., Am J Cardiol, 49:1659-66, 1982; Cohn et al., N Engl J Med, 311:819-23, 1984). Before the 1970s, managing heart failure aimed at improving the functional deficit of the left ventricular pump and relieving the resultant fluid accumulation with diuretic therapy (Weber, J Am Coll Cardiol, 44(6):1308-10, 2004). Although diuretic therapy has remained a mainstay of treatment, inotropic drug therapy was associated with adverse effects and no improvement in survival (Lee et al., N Engl J Med, 306(12):699-705, 1982; Guyatt et al., Am J Cardiol, 61(4):371-5, 1988). Consequently, since the 1970s, pharmacologic management has shifted more toward reducing the vascular bed's opposition to left ventricular emptying and inhibiting the vasoconstrictor and growth-promoting influences of neurohormonal stimulation that leads to left ventricular structural changes or remodeling (Cohn, Circulation, 48(1):5-8, 1973; Guiha et al., N Engl J Med, 291(12):587-92, 1974; Mikulic et al., Circulation, 56(4 Pt 1):528-33, 1977; Cohn and Franciosa, Am J Med, 65(1):181-8, 1978). This shift in emphasis has resulted in reduced dependence on digitalis and other positive inotropic interventions and greater reliance on angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), beta-adrenergic receptor blockers, aldosterone inhibitors, and newer agents that appear to inhibit vasoconstrictor and growth-promoting forces that contribute to the progression of the disorder (CONSENSUS Trial Study Group, N Engl J Med, 316(23):1429-35, 1987; The SOLVD Investigators, N Engl J Med, 325(5):293-302, 1991; Cohn et al., N Engl J Med, 345(23):1667-75, 2001; Packer et al., N Engl J Med, 334(21):1349-55, 1996; McMurray et al., N Engl J Med, 371(11):993-1004, 2014). This chapter addresses the evidence for neurohormonal activation in heart failure, data demonstrating a favorable effect of these neurohormonal modulators on the course of heart failure, and future therapeutic strategies that may be effective in slowing the growing burden of heart failure in the developed world.

KW - Heart failure

KW - Neurohormonal activation

KW - Renin-angiotensin system (RAS)

KW - Renin-angiotensin-aldosterone system (RAAS)

UR - http://www.scopus.com/inward/record.url?scp=85054624497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054624497&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-44577-9_16

DO - 10.1007/978-3-319-44577-9_16

M3 - Chapter

AN - SCOPUS:85054624497

SN - 9783319445755

SP - 239

EP - 246

BT - Congestive Heart Failure and Cardiac Transplantation

PB - Springer International Publishing

ER -